<DOC>
	<DOC>NCT01028404</DOC>
	<brief_summary>This trial is conducted in Europe. The aim of this trial is to investigate the safety, tolerance, pharmacokinetics (exposure of drug) and pharmacodynamics (effect) of NN1952 as tablets in healthy volunteers and subjects with type 1 and type 2 diabetes. The trial consists of two parts. In part 1, single escalating doses of NN1952, placebo or insulin aspart will be given to healthy volunteers. In part 2, subjects with type 1 or type 2 diabetes will receive single doses of NN1952 (with/without a meal), insulin aspart and placebo.</brief_summary>
	<brief_title>A Two Part Trial Investigating NN1952 in Healthy Subjects and Subjects With Type 1 and Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin, Long-Acting</mesh_term>
	<criteria>FOR TRIAL PART 1, THE FOLLOWING APPLIES: Gender: male Age: 1855 years BMI (body mass index): 1828 kg/m2 Study participants considered to be healthy FOR TRIAL PART 2, THE FOLLOWING APPLIES: Gender: male or female of no childbearing potential Age: 1865 years Type 1 diabetes: BMI (body mass index): 1828 kg/m2 Type 2 diabetes: BMI (body mass index): 2235 kg/m2 Type 1 or type 2 diabetes for at least 12 months Type 1 diabetes: Treatment with insulin for at least 12 months Type 2 diabetes: Treatment with insulin for at least 3 months Known or suspected allergy to the trial product or related products Presence of illness or infection that may confound the results of the study or pose a risk to the study participant by dosing NN1952, as judged by the Investigator Presence of acute gastrointestinal symptoms (for example nausea, vomiting, heartburn or diarrhoea)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>